Stay updated on Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial page.

Latest updates to the Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial page
- Check6 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check27 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check56 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check70 days agoChange DetectedThe webpage has been updated to reflect a new clinical trial involving Ixazomib for Recurrent Plasma Cell Myeloma, with significant details about the study's objectives and collaborators. The previous trial involving daratumumab has been removed, indicating a shift in focus.SummaryDifference55%
- Check77 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 6, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.2%
Stay in the know with updates to Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial page.